

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4140

TITLE: Characterization and Consequences of Estrogen Receptor  
Exon Five Deletion

PRINCIPAL INVESTIGATOR(S): Irina Erenburg  
Doctor Schacter

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine  
New York, New York 10029-6574

REPORT DATE: September 1995

TYPE OF REPORT: Annual

PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19960206 013

DTIC QUALITY INSPECTED 1

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

|  |  |   |   |  |
|--|--|---|---|--|
| 1. AGENCY USE ONLY (Leave blank)   |  | 2. REPORT DATE<br>September 1995                        | 3. REPORT TYPE AND DATES COVERED<br>Annual (9/1/94-8/31/95) |  |
| 4. TITLE AND SUBTITLE<br>Characterization and Consequences of Estrogen Receptor Exon Five Deletion   |  |   | 5. FUNDING NUMBERS<br>DAMD17-94-J-4140                      |  |
| 6. AUTHOR(S)<br>Irina Erenburg<br>Doctor Schacter  |  |   |   |  |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>Mount Sinai School of Medicine<br>New York, New York 10029-6574  |  |   | 8. PERFORMING ORGANIZATION REPORT NUMBER                    |  |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012  |  |   | 10. SPONSORING / MONITORING AGENCY REPORT NUMBER            |  |
| 11. SUPPLEMENTARY NOTES  |  |   |   |  |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for public release; distribution unlimited  |  |   | 12b. DISTRIBUTION CODE                                      |  |
| 13. ABSTRACT (Maximum 200 words)<br><br>Normal breast growth and development is dependent on estrogen signaling through the estrogen receptor (ER). In addition to its normal function, many studies have conclusively demonstrated the involvement of estrogen as a mitogen in breast tumors. The recent identification of estrogen receptor mRNA splice isoforms has lead to the hypothesis that de-regulation of ER pre-mRNA splicing contributes to the etiology of breast cancer. Data in this report begin to clarify the function of a non-DNA binding estrogen receptor isoform (ER $\Delta$ 3) in both tumor and normal breast biology.<br>Currently, our studies suggest that normal mammary epithelium contains significantly higher levels of ER $\Delta$ 3 mRNA than we have observed in breast tumors or tumor cell lines. In addition, MCF-7 cells (a breast tumor cell line) which have been stably transfected to overexpress ER $\Delta$ 3, gain a morphologically more differentiated phenotype, partially characterized by their ability to form domes with a hollow lumen, as well as their decreased growth rate in response to estrogen. These results have lead us to propose that ER $\Delta$ 3 functions to attenuate the responsiveness of normal mammary epithelium to the growth stimulatory effects of estrogen. Consequently, the loss of ER $\Delta$ 3 expression in breast tumors may enhance the mitogenic effects of estrogen, thereby contributing to disease progression. |  |   |   |  |
| 14. SUBJECT TERMS<br>Humans, Anatomical Samples, Breast Cancer   |  |   | 15. NUMBER OF PAGES<br>17                                   |  |
|  |  |   | 16. PRICE CODE  |  |
| 17. SECURITY CLASSIFICATION OF REPORT<br>Unclassified  | 18. SECURITY CLASSIFICATION OF THIS PAGE<br>Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT<br>Unclassified | 20. LIMITATION OF ABSTRACT<br>Unlimited                     |  |

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet optical scanning requirements.

**Block 1. Agency Use Only (Leave blank).**

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

|                      |                              |
|----------------------|------------------------------|
| C - Contract         | PR - Project                 |
| G - Grant            | TA - Task                    |
| PE - Program Element | WU - Work Unit Accession No. |

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number. (If known)**

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

**Block 12b. Distribution Code.**

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

       Where copyrighted material is quoted, permission has been obtained to use such material.

       Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

       Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

       In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

       For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

  X   In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

  X   In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

       In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

       *Irene Erenburg* 10/23/95  
PI - Signature                      Date

**Table of Contents:**

|                           | Page Number |
|---------------------------|-------------|
| <i>Introduction</i>       | 1           |
| <i>Results/Conclusion</i> | 6           |
| <i>Future Studies</i>     | 9           |
| <i>Bibliography</i>       | 10          |

## **INTRODUCTION**

Conclusive evidence implicate the ovarian steroid estrogen as one of the key regulators of normal breast growth and differentiation, and as a mitogen in breast tumors [1, 2]. Its function in tumors has led to the use of tamoxifen, an anti-estrogen, as an essential method of therapeutic intervention.[3] Estrogen receptor (ER) is the major mediator of estrogen action in both tumor and normal breast function but its precise role in the signaling pathways has not been clearly elucidated.

### ***Estrogen Effects on Normal Breast:***

At the onset of puberty in women, breast tissue undergoes growth and differentiation in response to the increased levels of circulating estrogens, forming the mature tissue. The non-lactating mature breast contains lobules of branched tubulo-alveolar glands with interlobular stroma and adipose tissue. The glands are lined by a simple cuboidal luminal epithelium with myoepithelial and stem cells located at the basement membrane. Surrounding the glands are stromal fibroblasts and myofibroblasts.

As mentioned above, estrogen is the primary hormone that triggers mammary gland maturation during puberty. It stimulates the proliferation of epithelium that ultimately leads to the development in the adult mammary gland of the complex network of branched ducts terminating in end-buds. Most of the proliferation in response to estrogen stimulation occurs in the duct epithelium [4].

Estrogen's effect on the mammary gland is not exclusively proliferative. It also induces the expression of the progesterone receptor (PR), which allows progesterone, acting through PR, to initiate differentiation of luminal epithelium and local proliferation of the end-buds [5]. Both the differentiative and end-bud proliferative signals of PR ultimately lead to the development of secretory alveoli. Thus, in normal breast growth, ER can be seen having both direct proliferative and indirect differentiative functions.

In the context of the adult non-lactating mammary gland the combined effects of ER and PR display a tightly regulated synchrony with the cyclical hormonal changes of the menstrual cycle. In the late follicular/early luteal stage, when estrogen production peaks, an increased proliferation rate and PR induction are observed in the mammary glands [6]. During the mid-to-late luteal phase increased progesterone levels act on the sensitized glands to initiate differentiation and end-bud development. If fertilization of the oocyte and embryo implantation do not occur, estrogen and progesterone levels drop and the end buds involute [6].

When implantation occurs, the corpus luteum of pregnancy continues to produce both estrogen and progesterone. The combined action of these hormones leads to the development of secretory alveoli - which reach a fully differentiated state soon after parturition. During lactation luminal epithelium becomes columnar with an increased level of endoplasmic reticulum marking its secretory function [7]. The myoepithelial and myofibroblast cells surrounding the alveoli contract to aid milk ejection from the glands.

Mammary gland secretion occurs via a mostly modified apocrine mechanism which involves continuous loss of cytoplasm and membrane [8].

### ***Estrogen Effects in Breast Cancer:***

As with most cancers, the development of breast cancer is believed to be a multi-step process. Infiltrating ductal carcinoma accounts for the majority of breast cancer cases (~85%) [9]. The progression of breast cancer is believed to begin with atypical hyperplasia, leading to an intraductal carcinoma or carcinoma in situ, that finally give rise to invasive ductal carcinoma [9]. Most often these cancers arise from the estrogen responsive luminal epithelium. Currently, all breast tumors, in addition to being clinically and pathologically staged, are also assayed for the presence of estrogen and progesterone receptors. Responsiveness to tamoxifen, a widely used adjuvant therapy, is best predicted by the presence of ER/PR in breast tumor tissue [3]. The ER negative/PR negative phenotype is usually associated with worse prognosis and more aggressive and invasive cancers [10].


The presence of estrogen receptor as a predictor of responsiveness to tamoxifen therapy is further supported by breast cancer cell line analysis. Such analyses have shown that estrogen's mitogenic signals are mediated via ER, which regulates the expression of several genes involved in proliferation [11, 12]. Two such critical genes products are cyclin D1, a partner of the cyclin dependent kinase 4 (cdk4) involved in the G1-S transition, and myc, a transcription factor essential for cell cycle progression [11, 12]. Both mRNAs and proteins are induced by estrogen, and inhibited by tamoxifen as well as other pure anti-estrogen compounds [11, 12]. The transcriptional control may occur through the classical pathways involving ER interacting with EREs, or alternatively through ER interacting with other transcription factors. In addition, in the case of myc, ER may also be involved in post-transcriptional control of mRNA stability [13].

Another class of estrogen regulated proteins are the proteolytic enzymes: plasminogen activators (PA) (urokinase-PA (u-PA) and tissue type-PA (t-PA), believed to function in the degradation of extracellular matrix by tumor cells during invasion and metastasis [14]. As such, u-PA is an independent predictor of poor prognosis in breast cancer [15]. Although the molecular mechanism of estrogen regulation of PAs remains unclear, induction of proteolytic activity by estrogen implicates ER not only in proliferation but also in the process of tumor invasion.

Consequences of estrogen induction of PR in breast tumors are not as clear. Much of the initial investigation of progesterone action was performed using the endometrium as the model where PR has no effects on proliferation but striking effects on differentiation [16]. The differences between progestin responses of the breast and endometrium do not allow for extrapolation of results from one system to the other. The mixed differentiative and proliferative effects of progesterone in normal breast tissue makes the investigation of its effects in breast tumors complex. Data suggests that in normal cells the interaction of progesterone with its receptor may commit the cells to differentiation, whereas in cells that have been damaged by a carcinogen the proliferative effects of progesterone predominate thus enhancing tumor formation [16].

## **Estrogen Receptor Structure and Function:**

The estrogen receptor (ER) belongs to a family of nuclear steroid receptors that regulate gene transcription. Structural analyses have shown distinct functional domains in the receptor: an amino terminal transactivating domain (A/B), a zinc finger DNA binding domain (C), and a carboxy terminal hormone binding domain (E/F) [17] (Fig 1).



In the absence of hormone, predominantly nuclear ER (four nuclear localization signals), exists in an oligomeric complex with several heat shock proteins (hsps) [18]. When bound to the hsp complex, ER is unable to activate gene transcription [19]. However, in the presence of estrogen, the complex dissociates and the ER dimers are free to interact with palindromic estrogen response elements (ERE's) of genes [20, 21].

Two regions of ER are involved in transcriptional regulation: transcriptional activation function-1 (TAF-1), located in the amino terminus (A/B), and transcriptional activation function-2 (TAF-2) located in the carboxy terminus (E/F) [22, 23]. TAF-1 interacts with other transcription factors independently of estrogen binding. The expression of genes controlled exclusively by TAF-1, such as IGF1 and alkaline phosphatase, is not inhibited by the addition of tamoxifen in tissues such as the endometrium [24] [25, 26]. Unlike the hormone independent function of TAF-1, TAF-2 requires estrogen binding for function. The estrogen bound TAF-2, by interacting with TAF-1, induces a class of genes that are sensitive to inhibition by tamoxifen [24]. Although, the two independent TAF's cooperate and enhance each other's transactivation activity, their individual contributions are promoter and cell type specific [18, 22, 23].

## **Splice Isoforms of the Estrogen Receptor: Function**

The estrogen receptor messenger RNA (mRNA) is encoded by a single copy gene in the human genome [27]. Recent studies have determined that multiple forms of the estrogen receptor arise from alternative splicing of the primary ER transcript. Messenger RNAs missing exon 3, 5, or 7 were first identified in primary breast tumors and breast cancer cell lines [28-31]. Initial studies by Fuqua et al. have shown that the skipping of exon 3 (ER $\Delta$ 3)

deletes the second zinc finger of the DNA binding domain and renders this form of the receptor incapable of binding DNA [29]. *In vitro* expression of the exon 5 (ER $\Delta$ 5) and exon 7 (ER $\Delta$ 7) spliced forms show that both exon skipplings create a frame shift that leads to premature termination of translation, thereby truncating these receptors in different portions of the hormone binding domain. Transient transfection of ER $\Delta$ 5 in conjunction with an ERE-CAT reporter, has demonstrated constitutive, hormone independent activity of this isoform [30]. My original proposal chose to focus on the function of ER $\Delta$ 5. At that time studies were ongoing for both the ER $\Delta$ 5 and ER $\Delta$ 3 splice isoforms. Subsequently, the data supported the further development of the ER $\Delta$ 3 isoform project. In addition, we were aware of several other groups who are investigating the role of ER $\Delta$ 5, using a similar approach as was discussed in my original proposal. Several such groups have recently published their results [32-34]. Accordingly, I will present and discuss data concerning the ER $\Delta$ 3 splice isoform in breast biology and estrogen responsiveness.

The consequence of exon skipping may have important implications for ER function. The only reported analysis of the distribution of ER $\Delta$ 3, outside of data in this report, is limited to primary breast tumors and cell lines. Once again only the original characterization performed by Fuqua et al. and limited analysis of breast tumors carried out by Miksicek et al. has identified the presence of ER $\Delta$ 3 mRNA in breast tumors; however, the problem of tissue heterogeneity complicates the interpretation of these studies [29, 35].

Functional analysis of the ER $\Delta$ 3 isoform is limited to a series of *in vitro* translation and transient transfection experiments, which demonstrated dominant negative activity of ER $\Delta$ 3 on ER function [29]. When ER $\Delta$ 3 was *in vitro* translated with ER, a concentration-dependent inhibition of ER-DNA binding was observed. Inhibition of ER binding to DNA by ER $\Delta$ 3 was ~25% when a 1:1 ratio of ER $\Delta$ 3/ER was used and increased to ~90% in a 10:1 co-translation ratio of ER $\Delta$ 3/ER, thereby suggesting random heterodimerization of ER $\Delta$ 3 with ER. These data were further confirmed in transient co-transfection experiments of HeLa cells. Transfection of ER and ER $\Delta$ 3 with an ERE-CAT reporter showed ER $\Delta$ 3 inhibition of the estradiol (E2)-stimulated ER transactivation [29].

#### ***Implications of ER $\Delta$ 3 on Breast Function:***


The finding of exon skipped ER isoforms requires re-investigation of estrogen effects in breast biology. We postulate that the existence of ER $\Delta$ 3 in normal tissue may either present cells with a mechanism for attenuating estrogen responsiveness or, alternatively, potentiate the mitogenic actions of this hormone. Current understanding of the function of this isoform in transcriptional regulation is limited to its inhibition of ER transactivation of a consensus ERE-CAT reporter [29]. If a similar effect can be shown *in vivo*, we can presume that regulation of ER $\Delta$ 3 expression may present a mechanism for cells to modulate sensitivity to hormone. Alternatively, ER $\Delta$ 3 may regulate the expression of target genes via DNA binding domain independent interaction with other transcription factors [36].

The involvement of ER $\Delta$ 3 in breast cancer is still unclear. Tissue heterogeneity of breast tumors complicates the interpretation of the cellular source of ER $\Delta$ 3 from total tissue. Until specific cellular localization is determined we cannot discriminate between low level of ER $\Delta$ 3 expression in all cells, versus over-expression in a subtype of normal or tumor cells.

The observation of dominant negative activity of ER $\Delta$ 3, combined with the existence of alternative pathways involving interactions with other transcription factors, permits us to generate two opposing hypotheses on the possible role of ER $\Delta$ 3 in breast cancer. Both models involve deregulation of ER $\Delta$ 3 expression in the process of tumor development. The first model assumes an increase, while the second assumes a decrease of ER $\Delta$ 3.


*I.* In the normal breast ER induces PR in response to estrogen. This induction primes the breast to respond to the differentiative effects of progesterone. In this model, overexpression of ER $\Delta$ 3 may inhibit estrogen stimulation of PR, thereby potentially allowing escape from the differentiative pathway and forcing cells into the proliferative pathway leading to hyperplasia. In addition, ER $\Delta$ 3 may, in fact, directly stimulate the expression of genes involved in proliferation by mechanism of regulation not depend on the DNA binding domain (DBD).

**MODEL I:**



*II.* The opposing model for ER $\Delta$ 3 action assumes that a basal expression of ER $\Delta$ 3 in normal breast is necessary to attenuate the proliferative effects of estrogen. Thus, we can hypothesize that loss of ER $\Delta$ 3 expression may create hyper responsiveness to estrogen stimulation via the classical pathway.

**MODEL II:**



In order to verify whether ER $\Delta$ 3 has a role in breast biology and which of the two models more accurately reflects the in vivo situation we are currently performing a series of experiments encompassing analysis of ER $\Delta$ 3 distribution in normal and tumor mammary tissue, as well as functional effects of ER $\Delta$ 3 overexpression on growth, invasiveness and gene

regulation. In the next section I will discuss the data from the analyses completed to date and the questions that remain to be addressed.

## **RESULTS:**

### ***Distribution Analyses: ER $\Delta$ 3:ER***

We screened a series of primary breast tumor tissues for the presence of ER $\Delta$ 3 mRNA. In order to facilitate the wide spectrum screen, we employed a semi-quantitative reverse transcription/PCR assay, optimized to reflect both increasing cycle number and total RNA input. Amplified products were size fractionated on replicate agarose gels and transferred onto nylon membranes. For each experiment, filters were probed with gamma-ATP<sup>32</sup> end-labeled oligonucleotides. One filter was hybridized with a probe homologous to an internal sequence of exon 4 which recognizes both full length ER and ER $\Delta$ 3, while the second filter was hybridized with a probe homologous to a portion of exon 3, which recognize only the full length ER. Both filters were washed under appropriate salt and temperature conditions, and exposed to a phosphorimager screen. Experiments were quantitated using the phosphorimager program ImageQuant to assess the ratio of ER:ER $\Delta$ 3 mRNA.

We have observed a range of ratios of ER $\Delta$ 3:ER among the breast tumors ranging between 1:2-1:30. With most specimens containing predominantly ER mRNA. The heterogeneity of total ER values and the ER $\Delta$ 3:ER ratios is not surprising in view of the well documented cellular heterogeneity of primary breast tumor tissue, with respect to the proportion of normal and tumor cells, and the cellular density of epithelial tumor and intervening stroma [9].

Before the *in vivo* role of ER $\Delta$ 3 can be elucidated, a cellular analysis must be performed to clearly identify the source of ER $\Delta$ 3 in these tumor tissues, as compared to the content of this isoform in normal breast. The major site of ER expression in the normal mammary gland are the luminal cells. We have assayed several normal cell specimens: three samples of normal myoepithelial mammary cells, four specimens of primary basal/stem epithelial cells, and two samples of luminal epithelial cells (all isolated from reduction mammoplasty tissue and identified using cell type specific keratin markers). In addition we have assayed an immortalized normal myoepithelial cell line (Hs578Bst), and an immortalized normal basal/stem cell line (MCF-10). As previously reported, the MCF-10 cells were ER-. However, in both the myoepithelial primary cells and Hs578Bst cells, we found a ~2:1 ratio of ER $\Delta$ 3:ER. Interestingly, the primary luminal cells had a predominance of ER mRNA with a ratio of ER $\Delta$ 3:ER of ~1:2. Although preliminary, these results suggest that certain normal mammary epithelial cells contain a ratio that is strikingly different from that seen in breast tumors above, suggesting that ER $\Delta$ 3 expression and ER $\Delta$ 3:ER ratio varies as a function of cell origin. However, the primary cell purification is especially difficult for luminal cells and we are in the process of collecting more specimens to confirm this finding. This analysis agrees with our assumption that the widely different ratios of ER $\Delta$ 3:ER in the breast tumors may reflect the normal/tumor cell heterogeneity of this tissue.

All of the analyses described so far have examined the mRNA levels of ER $\Delta$ 3. The protein product of this ER splice isoform has yet to be identified *in vivo*, an analysis complicated by

the lack of antibodies that specifically recognize the protein encoded by this splice isoform, as well as by the low abundance of ER and consequently lower levels of ER $\Delta$ 3. A recent report of detection of ER $\Delta$ 5 protein in a breast tumor cell line that was previously found to have high levels of the corresponding mRNA species, implies that alternative splicing of pre-mRNA may regulate the expression of ER protein isoforms *in vivo* [37]. Furthermore, in several published studies in which ER has been detected by western blot analysis, less abundant immunoreactive products of lower molecular weight than full length ER were noticed. In at least two such blots, a band is seen approximately in the size range expected for the predicted ER $\Delta$ 3 protein (~63kD) [38, 39].

To identify ER $\Delta$ 3 protein we have prepared specific antibodies to this isoform. We synthesized a peptide of 22 amino acids in length homologous to the junction of exon 2/exon 4, the only unique portion of the ER $\Delta$ 3 protein. The peptide, coupled to the carrier protein ovalbumin, was injected into rabbits for polyclonal antibody production and mice in an attempt to generate monoclonal antibodies. We have recently received serum from both rabbits and mice and are in the process of testing it for specificity. In addition to making specific ER $\Delta$ 3 antibodies we have established gel conditions in order to detect ER $\Delta$ 3 protein specifically by using a combination of immunoprecipitation and western blot with an antibody specific for an epitope in the zinc finger encoded by exon 3 and one that detects an epitope in the hormone binding domain. Using these antibodies we will identify the ER $\Delta$ 3 protein *in vivo* in the event that our ER $\Delta$ 3 specific antibody is unsuccessful.

### **Functional Studies:**

In order to understand the role ER $\Delta$ 3 in estrogen signaling, we must investigate both the distribution and function of this splice isoform. The ongoing analyses described above address the question of ER $\Delta$ 3:ER ratios *in vivo*. The subsequent data and further studies to be performed, will examine the role of ER $\Delta$ 3 in growth regulation, invasiveness and estrogen regulated gene expression.

To investigate the effects of altering the ER $\Delta$ 3:ER ratio on ER $\Delta$ 3 function, we chose ZR-75 and MCF-7 cells, both ER+, E2 responsive breast cancer cell lines. Both of these cell lines have been well-characterized with respect to responsiveness to both estrogens and antiestrogens, though they differ markedly in endogenous ER expression. MCF-7 cells contain high levels of ER, as also confirmed by our assay, and an ER $\Delta$ 3:ER mRNA ratio of approximately 1:10. In contrast, the ZR-75 cells contain low to moderate levels of ER and display ~1:5 ER $\Delta$ 3:ER ratio. The substantial amount of available information about ER actions in these cell lines allow us to define specific questions for studying effects of ER $\Delta$ 3 overexpression. Thus, we began preparing stably transfected clones of MCF-7 and ZR-75 cells overexpressing ER $\Delta$ 3.

We constructed an ER $\Delta$ 3 expression vector, by directionally ligating a restriction enzyme digested, gel purified partial ER cDNA clone, containing exon 1, 2 and 4, but missing exon 3, (gift of Miksicek et al.) into a similarly digested and purified HEGO vector containing the partial sequences of exon 1 and exons 4 through 8 of full length ER cDNA (gift of Chambon et al.). The ER $\Delta$ 3 ligation product in the parent HEGO expression vector was used to transform bacteria. DNA was purified using the Wizard Maxi-Prep kit from Promega.

Following digestion with EcoRI, the ERΔ3 coding sequence was gel purified as before, and ligated into an EcoRI digested and dephosphorylated retroviral expression vector, pMV-7, containing the neomycin resistance gene. This final mammalian expression vector with ERΔ3 under a MuLV promoter was used for all subsequent transfection experiments.

To confirm the ability of this newly constructed ERΔ3-pMV7 expression vector to express protein, the ER- Cos cells were transiently transfected and assayed for ERΔ3 expression by fluorescent immunocytochemistry with a specific antibody to the hormone binding domain of ER (H222 - gift of Greene et al.). Transient transfection was performed using lipofectin as per manufacturer's recommendations. Visualization and photography was performed using the Zeiss fluorescent microscope. Positive rhodamine staining was seen in cells transfected with ERΔ3, with no staining observed in surrounding cells. Staining indicated the ability of this construct to produce the expected protein *in vivo*. Nomarski imaging demonstrated that the specific staining was nuclear, as would be expected given that ERΔ3 retains several nuclear localization signals.

Prior to stably transfecting either MCF-7 or ZR-75 cells, sensitivity to the antiplastic geneticin (G418) for both cell lines was established. Lipofection was used to stably transfect cells with 3ug of either ERΔ3-pMV7 expression vector or an "empty" pMV7 vector control. Cells were allowed to recover overnight and placed into selection medium containing 400ug/ml (MCF-7) or 1mg/ml (ZR-75) G418, either in the absence or presence of  $1 \times 10^{-8}$  M Estradiol (E2). Transfected cells were maintained in these selection media for 1-2 months, at which time clones were isolated.

Since we did not observe any colonies in the ZR-75 transfections, these cells will not be discussed further. We suspect that the lack of transfection of these cells originates from their inability to form stable attachment with the substratum. From parallel transfection experiments of MCF-7 cells, we isolated approximately 25 clones of the ERΔ3-pMV7 expression vector and 20 clones of the pMV7 controls.

From the stable transfection of ERΔ3 in MCF-7 cells, yielded several G418 resistant colonies which were selected in csFBS/-E2, as well as some that were initially selected in FBS. Poor cell growth was observed by the second passage of several clones, as compared with control pMV7 transfectants. Most of the ERΔ3 transfected clones increased their growth rate by the third or fourth passage, prior to us having enough material to assay for ERΔ3 expression. However, at the fourth passage of two clones we had enough cells to plate cells in parallel into two 35mm dishes. One dish was maintained in csFBS and the other in FBS. The cells in FBS displayed significant cell death within 3 days, with one of the clones being drastically affected overnight. In contrast, the cells maintained in csFBS continued to grow. In response to this result we transferred all ERΔ3 transfected cells into csFBS containing medium. Unlike the growth inhibition by full serum observed in ERΔ3 transfectants, pMV7 transfected controls exhibited no growth retardation in FBS supplemented serum. Subsequent RT/PCR analysis revealed low expression of ERΔ3 in several clones and all controls tested, however, one of the clones that died in the presence of FBS showed ~2:1 ratio of ERΔ3:ER mRNA compared to the 1:10 ratio present in the parental cell line. Analysis of the second clone which was more severely affected by FBS showed that at the sixth

passage no significant overexpression of ERΔ3. When the experiment of plating the cells in csFBS or FBS was repeated with these later passage cells no difference in cell growth was observed. The RT/PCR analysis identified one other ERΔ3 overexpression clone. These results suggest that the overexpression of ERΔ3 renders these cells incapable of growth in the presence of even low concentrations of estrogen (FBS contains  $\sim 1 \times 10^{-12}$  M estradiol, whereas physiologic levels are  $\sim 1 \times 10^{-9}$  M). It is possible that the cells that lost their sensitivity to estrogen in the later passages had undergone an adaptive mechanism to reverse the growth inhibitory effects of ERΔ3 by inhibiting its expression. Similar phenomena have been seen in studies of tumor suppresser genes.

In addition to the growth retardation, the morphology of these clones differs from the pMV7 controls and from the non-overexpressing clones. The overexpressers form circular domes in which the cells appear to be arranged around structures that approximate glandular lumens that have been observed when normal luminal mammary epithelial cells are plated on plastic. In addition the cells have are more organized and appear more cuboidal than the controls. The changes further support a less transformed phenotype resulting from ERΔ3 expression. However, though these initial observations are encouraging we must await full characterization of the stable transfectants to conclusively characterize the function of ERΔ3 in breast epithelium.

The expression of ERΔ3 protein has been confirmed in the clones that overexpressed the mRNA using the specific hormone binding domain and exon 3 specific antibodies previously described. The level of ERΔ3 protein expression is approximately equal to the amount of endogenous estrogen receptor in the MCF-7 cells (ratio of 1:1 ERΔ3:ER). The lack of gross overexpression that is often observed in transfectants further supports the growth consequences of ERΔ3 expression. Having now established both gel conditions that separate the 67kD ER from the 63kD ERΔ3 as well as *gaining* positive control cells that express ERΔ3 at a easily detectible level we will be able to proceed with the analysis of the antibodies that we have generated, as well as aid in the identification of ERΔ3 in primary breast cells.

## **FUTURE STUDIES**

Having generated breast tumor cells stably transfected with ERΔ3, we can now perform functional studies to delineate the role of ERΔ3 in estrogen signaling. Thus MCF-7 cells overexpressing ERΔ3 will be assayed for responsiveness to estrogen and antiestrogens with endpoints such as growth, invasive potential, and estrogen target gene regulation. If ERΔ3 overexpression in fact confers a less transformed phenotype to breast cancer cells, this may suggest that of the two models presented at the end of the introduction, Model II is correct. Thus, if ERΔ3 is expressed in higher levels in normal breast epithelium than in breast tumor cells, as suggested by the normal breast cell analysis described above, a decrease or loss of ERΔ3 expression may promote cancer progression by stimulating estrogen mediated mitogenic actions. Such a mechanism of action may ultimately lead to the development of new therapies to differentiate breast tumor cells by identifying factors that regulate the estrogen receptor RNA splicing *in vivo*.

## **Bibliography**

1. Taylor-Papadimitriou, J., Wetzels, R., Ramaekers, F., *Intermediate filament protein expression in normal and malignant mammary epithelial cells.*, in *Genes, oncogenes and hormones. Advances in cellular and molecular biology of breast cancer.*, R.B. Dickson, Lippman, M.E., Editor. 1992, Kluwer Academic Publishers: Boston. p. 355-378.
2. Habel, L.A., Stanford, J.L., *Hormone receptors and breast cancer.* *Epidemiologic reviews*, 1993. **15**(1): p. 209-219.
3. Plowman, P.N., *Tamoxifen as adjuvant therapy in breast cancer current status.* *Drugs*, 1993. **46**(5): p. 819-833.
4. Lippman, M.E., Dickson, R.B., *Regulation of normal and malignant breast epithelial proliferation.*, in *Growth Regulation of Cancer II*. 1990, A.R. Liss, Inc.: Washington, D.C. p. 127-172.
5. Topper, Y.J., Freeman, C.S., *Multiple hormone interactions in the development biology of the mammary gland.* *Physiological Reviews*, 1980. **60**(4): p. 1049-1106.
6. Yen, S., Jaffe, R., *Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management*, in *Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management*, S. Boyd, Editor. 1986, W. B. Saunders Company: Philadelphia. p. 315-316; 674-675.
7. Grey, H., *Gray's Anatomy*, in *Splanchnology: The mammae or mammary glands*, P.L. Williams, Warwick, R., Dyson, M., Bannister, L.H., Editor. 1989, Churchill Livingstone: London. p. 1447-1450.
8. Wheater, P.R., *Wheater's Functional Histology*, in *Wheater's Functional Histology: A Text and Colour Atlas*, H.G. Burkitt, Young, B., Heath, J. W., Editor. 1993, Churchill Livingstone: London. p. 362-365.
9. Underwood, J.C.E., *General and Systemic Pathology*. 1992: Churchill Livingstone.
10. Haber, D.A., Park, S., Maheswaran, S., Englert, C., Re, G.G., Hazen-Martin, D.J., Sens, D.A., Garvin, A.J., *WT1-mediated growth suppressin of Wilms tumor cells expressing a WT1 splicing variant.* *Science*, 1993. **262**: p. 2057-2059.
11. Watts, C.K.W., Sweeney, K.J.E., Warlters, A., Musgrove, A., Sutherland, R.L., *Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells.* *Breast Cancer Research and Treatment*, 1994. **31**: p. 95-105.
12. Dubik, D., Shiu, R.P.C., *transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells.* *The Journal of Biological Chemistry*, 1988. **263**(25): p. 12705-12708.

13. Santos, G.F., Scott, G.K., Lee, W.M.F., Liu, E., Benz, C., *Estrogen-induced post-transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells*. The Journal of Biological Chemistry, 1988. **263**(20): p. 9565-9568.
14. Mignatti, P., Rifkin, D.B., *Biology and biochemistry of proteinases in tumor invasion*. Physiological Reviews, 1993. **73**(1): p. 161-194.
15. Grondahl-Hansen, J., Christensen, I.J., Rosenquist, C., Brunner, N., Mouridsen, H.T., Dano, K., Blichert-Toft, M., *High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis*. Cancer Research, 1993. **53**(June): p. 2513-2521.
16. Horwitz, K.B., *The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer*. Endocrine Reviews, 1992. **13**(2): p. 146-163.
17. Kumar, v., Green, S., Stack, G., Berry, M., Jin, J. R., Chambon, P., *Functional domains of the human estrogen receptor*. Cell, 1987. **51**: p. 941-951.
18. Parker, M.G., *Action of "pure" antiestrogens in inhibiting estrogen receptor action*. Breast Cancer Research and Treatment., 1993. **26**: p. 131-137.
19. Chambraud, B., Berry, M., Redeuilh, G., Chambon, P., Baulieu, E. E., *Several regions of human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes*. Journal of Biological Chemistry, 1990. **265**(33): p. 20686-10691.
20. Smith, D.F., *Dynamics of heat shock protein 90 - progesterone receptor binding and the disactivation loop model for steroid receptor complexes*. Molecular Endocrinology, 1993. **7**(11): p. 1418-1429.
21. Carson-Jurica, M.A., Schrader, W.T., O'Malley, B.W., *Steroid receptor family: structure and functions*. Endocrine Reviews, 1990. **11**(2): p. 201-220.
22. Ing, N.H., Tsai, S.Y., Tsai, M.J., *Progesterone and estrogen*. Genes in Mammalian Reproduction, 1993: p. 271-291.
23. Gronemeyer, H., Benhamou, B., Berry, M., Bocquel, M. T., Gofflo, D., Garcia, T., Lerouge, T., Metzger, D., Meyer, M. E., Tora, L., Vergezac, A., Chambon, P., *Mechanisms of antihormone action*. Journal of Steroid Biochemistry and Molecular Biology, 1992. **41**(3-8): p. 217-221.
24. Tzukerman, M.T., Esty, A., Santiso-Mere, D., Danielian, P., Parker, M.G., Stein, R.B., Pike, J.W., McDonnell, D.P., *Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions*. Molecular Endocrinology, 1994. **8**(1): p. 21-30.
25. Huynh, H.T., Pollak, M., *Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI182780*. Cancer Research, 1993. **55**(December): p. 5585-5588.

26. Albert, J.L., Sundstrom, S. A., Lyttle, C. R., *Estrogen regulation of placental alkaline phosphatase gene expression in human endometrial adenocarcinoma cell line*. Cancer Research, 1990. **50**(June): p. 3306-3310.
27. Ponglikitmongkol, M., Green, S., Chambon, P., *Genomic organization of the human estrogen receptor gene*. EMBO Journal, 1988. **7**(7): p. 3385-3388.
28. Fuqua, S.A.W., Allred, D. C., Elledge, R.M., Krieg, S.L., Benedix, M. G., Nawaz, Z., O'Malley, B. W., Greene, G. L., McGuire, W. L., *The ER-positive / PR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain*. Breast Cancer Research and Treatment, 1993. **26**: p. 191-202.
29. Miksicek, R.J., Lei, Y., Wang, Y., *Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells*. Breast Cancer Research and Treatment, 1993. **26**(163-174).
30. Fuqua, S.A.W., Fitzgerald, S. D., Chamness, G. C., Tandon, A. K., McDonnell, D. P., Nawaz, Z., O'Malley, B. W., McGuire, W. L., *Variant human breast tumor estrogen receptor with constitutive transcriptional activity*. Cancer Research, 1991. **51**(105-109).
31. Fuqua, S.A.W., Fitzgerald, S. D., Allred, D. C., Elledge, R.M., Nawaz, Z., McDonnell, D. P., O'Malley, B. W., Greene, G. L., McGuire, W. L., *Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors*. Cancer Research, 1992. **52**: p. 483-486.
32. Klotz, D.M., Castles, C. G., Fuqua, S. A., Spriggs, L. L., Hill, S. M., *Differential expression of wild-type and variant mRNAs by stocks of MCF-7 breast cancer cells may account for differences in estrogen responsiveness*. Biochemical and Biophysical Research Communications, 1995. **210**(2, May 16): p. 609-615.
33. Castles, C.G., Klotz, D. M., Fuqua, S. A., Hill, S. M., *Coexpression of wild-type and variant oestrogen receptor mRNAs in a panel of human breast cancer cell lines*. British Journal of Cancer, 1995. **71**(5, May): p. 974-980.
34. Fuqua, S.A., *Estrogen receptor mutagenesis and hormone resistance*. Cancer, 1994. **74**(August 1, 3 Supplement): p. 1026-1029.
35. Fuqua, S.A.W., Chamness, G.C., McGuire, W.L., *Estrogen receptor mutations in breast cancer*. Journal of Cellular Biochemistry., 1993. **51**: p. 135-139.
36. Kushner, P.J., Hort, E., Shine, J., Baxter, J.D., Greene, G.L., *Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens*. Molecular Endocrinology, 1990. **4**(10): p. 1465-1473.
37. Castles, C.G., Fuqua, S. A. W., Klotz, D. M., Hill, S. M., *Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line*. Cancer Research, 1993. **53**(December 15): p. 5934-5939.

38. Auricchio, F., Di Domenico, M., Migliaccio, A., Castoria, G., Bilancio, A., *The role of estradiol receptor in the proliferative activity of vanadate on MCF-7 cells*. Cell Growth & Differentiation, 1995. 6(February): p. 105-113.
39. Borrás, M., Hardy, L., Lempereur, F., El Khissiin, A.H., Legros, N., Gol-Winkler, R., Leclercq, G., *Estradiol-induced down-regulation of estrogen receptor. Effect of various modulators of protein synthesis and expression*. Journal of Steroid Biochemistry and Molecular Biology, 1994. 48(4): p. 325-336.